Private Advisor Group LLC Purchases 566 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Private Advisor Group LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 11.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,435 shares of the medical research company’s stock after buying an additional 566 shares during the period. Private Advisor Group LLC’s holdings in IQVIA were worth $958,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of IQV. American National Bank & Trust bought a new stake in shares of IQVIA in the 1st quarter valued at $26,000. Golden State Wealth Management LLC grew its holdings in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after purchasing an additional 130 shares during the period. ST Germain D J Co. Inc. increased its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA during the 4th quarter worth about $39,000. Finally, Larson Financial Group LLC grew its stake in shares of IQVIA by 109.9% in the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after buying an additional 144 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE IQV opened at $199.17 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The firm has a fifty day moving average price of $157.09 and a 200-day moving average price of $170.04. The stock has a market cap of $33.86 billion, a PE ratio of 28.82, a price-to-earnings-growth ratio of 2.18 and a beta of 1.30.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the business posted $2.64 EPS. IQVIA’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Truist Financial increased their target price on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. HSBC lowered shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price target for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Cowen restated a “buy” rating on shares of IQVIA in a report on Wednesday. Finally, Redburn Partners set a $188.00 price objective on shares of IQVIA in a report on Friday, May 23rd. Seven investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $228.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.